[1] 蔡建生, 彭志坚, 黄俊益, 李继锋. 阿托伐他汀对老年性高血压并高血压肾病的影响 [J]. 广东医学 2006.doi:10.3969/j.issn.1001-9448.2006.05.075
[2] 林萍, 楼玲莉, 周智林, 郑凤鸣. 阿托伐他汀对动脉粥样硬化及血脂的临床价值探讨 [J]. 心脑血管病防治 2004.doi:10.3969/j.issn.1009-816X.2004.03.012
[3] 谢良地. HMG-CoA还原酶抑制剂的非调脂作用及机制(上) [J]. 高血压杂志 2004.doi:10.3969/j.issn.1673-7245.2004.03.028
[4] 赵水平, 张大庆. 阿托伐他汀对脂肪细胞功能的影响 [J]. 中华心血管病杂志 2003.doi:10.3760/j:issn:0253-3758.2003.11.014
[5] 成威, 周胜华, 罗顶世, 张铭, 李旭平, CHENG Wei, ZHOU Sheng-hua, LUO Ding-shi, ZHANG Ming, LI Xu-ping. 阿托伐他汀对高血压肾病蛋白尿和炎症的治疗作用 [J]. 中国现代医学杂志 2006.doi:10.3969/j.issn.1005-8982.2006.02.003
[6] 彭俊, 许祖芳, 王祥贵, 陈友佳. 阿托伐他汀对急性冠脉综合征患者介入术后肾功能的影响 [J]. 江西医药 2011.doi:10.3969/j.issn.1006-2238.2011.05.025
[7] Jo S H, Koo B K, Park J S. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography(PROMISS)trial--a randomized controlled stud [J]. American Heart Journal 2008, 155(03).
[8] EPSTEIN M, CAMPESE M D. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function [J]. American Journal of Kidney Diseases 2005, 45(01).
[9] Yokota N, O'Donnell M, Daniels F, Burne Taney M, Keane W, Kasiske B, Rabb H. Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury. [J]. American Journal of Nephrology 2003, 1(1).
[10] 陈汝筑, 黄守坚. 治疗药理学 [M]. 北京:人民卫生出版社 2003.
[11] Aronov DM. Statins: therapeutic cascade of their effects [J]. Кардиология 2004, 10(10).
[12] Pit B, Waters D, Brown W V. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease Atorvastatin versus Revascularization Treatment Investigator [J]. New England Journal of Medicine 1999, 341(02).
[13] 茹雪. 急性冠脉综合征早期他汀类药物的临床应用价值 [J]. 临床心血管病杂志 2004, 25(02).
[14] Athyros V G, Mikhailidis D P, Papageorgiou A A. The effect of statins versus untreated dyslipidemia on renal function in patients with coronary heart disease.A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study [J]. Journal of Clinical Pathology 2004, 57(07).
[15] Epstein M, Campese V M. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function [J]. American Journal of Kidney Diseases 2005, 45(01).
[16] Mcculough P A. Chronic Kidney disease:tipping the scale to the benefit of angiotension-converting enzyme inhibitors in patients with coronary artery disease [J]. Circulation 2006, 114(01).
[17] 侯仁荣. 阿托伐他汀对高血压肾病患者肾功能的影响 [J]. 中国中医咨询 2010, 2(08).
[18] Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. [J]. Kidney International: Official Journal of the International Society of Nephrology 2001, 1(1).
[19] McMurray JJ, Kjekshus J, Gullestad. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. [J]. Circulation 2009, 22(22).
[20] McMurray JJ, Kjekshus J, Gullestad. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. [J]. Circulation 2009, 22(22).
[21] Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. [J]. Journal of the American College of Cardiology 2008, 15(15).
[22] Molitch M E. Management of dyslipidemias in patients with diabetes and chronic kidney disease [J]. Clin J Am Soc Nephrol 2006, 1(05).
[23] Michael J. Koren, Michael H. Davidson, Daniel J. Wilson, Rana S. Fayyad, Andrea Zuckerman, David P. Reed. Focused Atorvastatin Therapy in Managed-Care Patients With Coronary Heart Disease and CKD [J]. American Journal of Kidney Diseases: The official journal of the National Kidney Foundation 2009, 5(5). |
